This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS Specific Aim: PPAR-? ligands are a useful and safe medical therapy for Adrenocorticotrophic Hormone (ACTH)-secreting pituitary tumors (Cushing s disease). As ACTH-secreting pituitary tumors exhibit abundant peroxisome proliferator activated receptor-gamma (PPAR-?) expression and the PPAR-? ligand rosiglitazone exerts potent anti-hormonal and anti-proliferative effects in in vitro and in vivo corticotroph tumor models, the effects of rosiglitazone on pituitary tumor growth, and pituitary tumor ACTH and adrenal steroid hormone secretion will be tested. The potential role of the PPAR-? ligand rosiglitazone in treating Cushing s disease will be examined in a Phase II clinical trial involving 15 patients with ACTH-secreting pituitary tumors (Cushing s Disease), who are newly diagnosed. The study will examine: (1) effects of rosiglitazone treatment on abrogating hypercortisolism, and (2) effects of rosiglitazone treatment on abrogating pituitary corticotroph growth. Additionally the effects, if any, of rosiglitazone treatment on abrogating plasma ACTH levels and inflammatory markers (C-reactive protein, IL-6, serum sialic acid, soluble intracellular and vascular adhesion molecules (sICAM-1, and sVCAM-1), and amyloid A) will be examined.
Showing the most recent 10 out of 1085 publications
